A dual-action medication called survodutide demonstrated markedly greater weight reduction than placebo in adults with obesity but without diabetes, according to results from a phase 3 trial presented at a major diabetes conference.
The figures from the SYNCHRONIZE-1 trial reveal that survodutide, which targets both glucagon and GLP-1 receptors, produced substantially more weight loss compared with a dummy treatment in participants who had obesity but did not have diabetes. The data was presented at the American Diabetes Association’s Scientific Sessions conference.
The Trial Results
Phase 3 trials represent the final stage of testing before potential regulatory approval, involving larger numbers of participants to confirm a treatment’s effectiveness and monitor side effects. The SYNCHRONIZE-1 study specifically examined adults with obesity – typically defined as having a body mass index of 30 or above – who did not have diabetes.
Survodutide works differently from existing weight loss medications by acting on two hormone pathways simultaneously. It targets both GLP-1 receptors, which help regulate blood sugar and slow stomach emptying, and glucagon receptors, which affect metabolism and energy balance.
What Makes This Different
The dual-action approach sets survodutide apart from current weight loss treatments. Most existing medications work through single pathways, but this drug’s ability to activate both receptor types could explain the enhanced weight reduction seen in the trial data.
Current weight loss medications approved for use include semaglutide and liraglutide, both GLP-1 receptor agonists that have shown effectiveness in clinical trials. But the addition of glucagon receptor activity represents a new therapeutic strategy.
The New England Journal of Medicine published the full trial results, indicating the research has undergone rigorous peer review. Such publication in a leading medical journal suggests the findings meet high scientific standards for methodology and analysis.
Next Steps for Approval
Before any new medication reaches patients, it must complete regulatory review processes. In the UK, the Medicines and Healthcare products Regulatory Agency evaluates clinical trial data for safety and efficacy before granting marketing authorisation.
The National Institute for Health and Care Excellence would then assess whether the treatment represents good value for the NHS, considering both clinical benefits and costs compared with existing options.
Source: @NEJM
Key Takeaways
- Survodutide showed markedly greater weight loss than placebo in phase 3 trial participants with obesity but without diabetes
- The medication works through dual action on both GLP-1 and glucagon receptors, a different approach from current treatments
- Results were published in the New England Journal of Medicine after presentation at a major medical conference
What This Means for Kent Residents
While survodutide remains in development and is not yet available to patients, Kent residents struggling with weight management can access existing NHS services through their GP or by calling NHS 111 for guidance. Current evidence-based treatments include lifestyle interventions, existing prescription medications where appropriate, and surgical options for eligible patients. Those interested in weight management should discuss all available options with their healthcare provider rather than waiting for potential new treatments that may take years to reach the NHS.
New Weight Loss Drug Shows Promise in Major Clinical Trial Quiz
5 questions